News

Pegylated Interferon Benefits High-Risk MPNs Previously Treated With Hydroxyurea

According to a study published in Blood, Pegylated interferon proved to be effective for patients with high-risk ET and PV.

New Clinical Trials Available for MPN Patients

Vactosertib and PRT543 are now available.

Patient Power's MPN Patient Survey

As researchers around the world seek to accelerate progress in medicine it's important for patients to share their stories to promote greater understanding. Patient Power has partnered with Dr. Naveen Pemmaraju to find out more about how patients use online resources to guide their car

New Trial Recruiting Primary, Post-PV, and Post-ET Myelofibrosis Patients

CTI Biopharma is recruiting patients for the PACIFCA trial, a randomized phase 3 study evaluating PACRITINIB in patients with MF.

The Fall 2019 Newsletter is Here

Your copy of the Fall 2019 Newsletter from the MPN Research Foundation is now available.

Pegylated Interferon Leads to High Response Rates in ET & PV After Hydroxyurea

ASH Clinical News reports on the results of an open-label, phase II clinical trial published in Blood.

Today is Rare Cancer Day!

The big day is here - Rare Cancer Day! Launched by the National Organization for Rare Disorders (NORD) and the NORD Rare Cancer Coalition, the goal of #RareCancerDay is to raise critical awareness of rare cancers and the need for greater research funding and patient support.

Geron Receives Fast Track Designation to Imetelstat for Myelofibrosis

More possible good news for upcoming therapies for myeloproliferative neoplasms. Geron was granted fast-track designation by FDA for imetelstat, which they have pursued in people with Intermediate-2 Myelofibrosis

MPN Research Foundation Announces 2019-2020 Grantees for MPN Challenge Grant program

The MPN Research Foundation is thrilled to announce the award of seven new projects as part of the MPN Challenge Grant program, a partnership between MPNRF and The Leukemia & Lymphoma Society. The following projects applied and reviewed in a competitive, peer-reviewed process that took place this past July in Chicago.

Pegasys users may now access resources to help with reimbursement issues through Genentech

For more information about the Genentech Patient Foundation and to learn if a patient receiving a Genentech product (such as Pegasys) is eligible to receive support, please visit www.gene.com/patients/patient-foundation or call the Patient Resource Center at 877-GENENTECH.

Patient Advocates Take Aim at Progression in Myeloproliferative Neoplasms

Through a one-year pilot grant, the MPN Research Foundation (MPNRF) will provide funding to Dr. Ann Mullally and Dana-Farber Cancer Institute's Center for Prevention of Progression (CPOP) to study the genomic basis for MPN disease progression

Imago BioSciences Granted Fast Track Designation for IMG-7289 in Myelofibrosis

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of myelofibrosis.

Blood Cancer Awareness Month 2019

September provides the MPN community a unique opportunity to draw attention to polycythemia vera, essential thrombocythemia, and myelofibrosis by celebrating nationally recognized Blood Cancer Awareness Month.

A method for detecting mutations and measuring gene-expression levels in the same cell has enabled an investigation into the effects of mutations in a specific gene on the emergence of a form of blood cancer..

Targeting the Aurora Kinase A Inhibition has potential benefit for patients with myelofibrosis.